REG - Oxford Biomedica PLC - Board Appointment

Oxford BioMedicaAnnouncement

13/04/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220413:nRSM1893Ia&default-theme=true

RNS Number : 1893I  Oxford Biomedica PLC  13 April 2022

 

 

Oxford Biomedica Appoints Namrata P Patel as Non-Executive Director

Oxford, UK - 13 April 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford
Biomedica" or "the Company"), a leading gene and cell therapy group, announces
the appointment of Ms. Namrata P Patel to the Board as an Independent
Non-Executive Director with immediate effect.

 

Ms. Patel has extensive international experience in manufacturing and end to
end Supply Chain with experience in the commercialised regulated industry. She
is currently SVP, Product Supply, within the Global Beauty Sector at Procter
& Gamble (NYSE: PG), a US-listed, multi-national consumer goods business,
having joined the company 25 years ago. Ms. Patel has held senior positions
across several major global markets, and plays a key role in delivering on
Procter & Gamble's 2040 Sustainability Ambition Goals for its Beauty
Business portfolio.

 

Over the course of her career, Ms. Patel has worked at a number of major
multi-national corporations, holding senior positions at Gillette, WH Smith
and Coca-Cola, with a strong focus on international supply chain management.
She holds a Masters in Logistics and Management from the Cranfield School of
Management, and a BA in Public Administration & Marketing from the
University of South Wales, Mid Glamorgan.

 

Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: "Namrata
is a high calibre and timely appointment for Oxford Biomedica as we advance
our manufacturing and CMC capabilities, whilst expanding our global presence.
We warmly welcome her to the Board and look forward to utilising her
international manufacturing and supply chain expertise, as well as her
experience in sustainability as we deliver on our aim of becoming a global
fully integrated viral vector leader."

 

Ms. Namrata Patel said: "Oxford Biomedica is at an exciting time in its
development as it broadens its scope into AAV and significantly expands its
manufacturing capacity to meet the growing global demand for its viral vector
capabilities. I look forward to working closely with the rest of the Board and
the management team as the Company continues to progress as a global leader in
the gene and cell therapy space."

 

Relevant disclosures

 

There are no disclosures required to be made in accordance with LR 9.6.13R.

 

 

-Ends-

 

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Neal

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell
therapy group. In January 2022, Oxford Biomedica announced that it was
broadening its leading viral vector offerings by incorporating Homology
Medicines' established AAV capabilities into a newly formed AAV Manufacturing
and Innovation Business in the US with Homology Medicines as a 20% owner. To
date, Oxford Biomedica and its subsidiaries (the "Group") have built a sector
leading lentiviral vector delivery platform (LentiVector®), which the Group
leverages to develop in vivo and ex vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of gene and
cell therapy product candidates in the areas of oncology, CNS disorders and
liver diseases. The Group has also entered into a number of partnerships,
including with Novartis, Bristol Myers Squibb, Boehringer Ingelheim, Beam
Therapeutics, Arcellx, Cabaletta, Orchard Therapeutics and Santen, through
which it has long-term economic interests in other potential gene and cell
therapy products. Additionally, the Group has signed a 3-year master supply
and development agreement with AstraZeneca for large-scale manufacturing of
the adenoviral based COVID-19 vaccine, AZD1222. Oxford Biomedica is based
across several locations in Oxfordshire, UK and employs more than 740 people.
Further information is available at www.oxb.com (http://www.oxb.com) .

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAGPUMACUPPGBP